Impact of Citrate Buffer Molarity on mRNA-LNP Formulation and Function

Study Background and Research Question

Lipid nanoparticles (LNPs) have rapidly become a foundational platform for delivering RNA therapeutics, including small interfering RNA (siRNA) and messenger RNA (mRNA) for vaccination and gene regulation applications. Their ability to encapsulate and protect nucleic acids, combined with bioavailability and biocompatibility, has driven their adoption in clinical products such as Onpattro® (siRNA) and mRNA-based vaccines (Comirnaty®, Spikevax®, mRESVIA™) (source: paper). While much attention has focused on lipid composition and mixing parameters, less is known about how the buffer conditions—specifically citrate buffer molarity used to dissolve mRNA prior to encapsulation—influence particle properties and biological performance. The central research question addressed is: Does the molarity of citrate buffer used in the aqueous phase during LNP preparation alter the critical quality attributes and functional delivery efficiency of mRNA-LNPs?

Key Innovation from the Reference Study

Binici et al. (2025) provide a systematic evaluation of how citrate buffer molarity affects LNP formation, beyond the routinely reported critical quality attributes (CQAs) such as particle size, polydispersity index (PDI), and encapsulation efficiency. By formulating SM-102-based LNPs encapsulating firefly luciferase mRNA across a range of citrate molarities (50 mM, 100 mM, 300 mM), the study uncovers that subtle changes in buffer composition can have a pronounced effect on functional outcomes, especially transfection efficiency, even when standard CQAs remain unchanged (source: paper).

Methods and Experimental Design Insights

The authors utilized an ethanol-injection/mixing methodology, employing SM-102 as the ionizable lipid, to prepare LNPs encapsulating firefly luciferase mRNA. The aqueous phase consisted of citrate buffer at varying molarities (50, 100, or 300 mM), a parameter typically chosen for mRNA stability and solubility. All LNP formulations were characterized for average particle size (z-average), PDI, and encapsulation efficiency. To probe functional differences, in vitro transfection of reporter mRNA and in vivo expression in mice were measured using luciferase assays (source: paper).

Protocol Parameters

• mRNA type | Firefly luciferase mRNA with Cap 1 structure | mRNA delivery and translation efficiency assay | Cap 1 structure enhances translation and reduces innate immune response | product_spec
• Buffer molarity | 50–300 mM citrate | mRNA-LNP formulation | Higher molarity (300 mM) reduces in vitro and in vivo transfection | paper
• Particle size | ~50–100 nm | LNP quality control | Optimal size for delivery; no major differences across buffer molarity | paper
• Encapsulation efficiency | High (>90%) | LNP formulation | Consistently high, unaffected by buffer molarity | paper
• In vivo imaging reporter | Firefly luciferase mRNA | in vivo bioluminescence imaging | Enables quantification of expression in animal models | paper
• Poly(A) tail length | ~100 nt | mRNA stability | Supports transcript longevity and protein output | product_spec

Core Findings and Why They Matter

Particle Characterization: Across all tested citrate molarities, LNPs exhibited low PDI and high encapsulation efficiency, with no significant differences in average particle size. However, closer analysis of particle size sub-populations (D10, D50, D90) and morphology indicated that higher citrate concentrations may subtly alter lipid packing during LNP formation (source: paper).

Transfection Efficiency: The most pronounced effect was observed at the functional level: LNPs formulated with 300 mM citrate buffer showed significantly reduced cellular uptake and in vitro transfection compared to those prepared with 50 mM or 100 mM citrate. This trend was mirrored in vivo, where luciferase expression in mice was considerably lower for the high-molarity formulation, despite comparable CQA metrics (source: paper).

Implications: These findings highlight the risk of relying solely on standard CQAs for LNP development and underscore the importance of functional assays (such as gene regulation reporter assays or in vivo bioluminescence imaging) in detecting subtle but impactful formulation differences.

Comparison with Existing Internal Articles

Several internal articles have addressed the role of mRNA structural features—especially the Cap 1 structure and poly(A) tail—in enhancing mRNA stability and translation, which is critical for robust bioluminescent reporter assays (internal article). While these resources focus on molecular engineering, the current reference study brings attention to the less-explored formulation variables—such as citrate buffer molarity—that can further modulate delivery outcomes. For example, this article discusses how firefly luciferase mRNA with Cap 1 structure enables sensitive and reproducible mRNA delivery and reporter assays, but does not directly address how formulation process variables (like buffer composition) intersect with these molecular optimizations.

The present study bridges this gap by demonstrating that even when capped mRNA for enhanced transcription efficiency is used, LNP process parameters can override or diminish the expected benefits if not carefully optimized (source: paper).

Limitations and Transferability

One limitation is the specificity of the study to SM-102-based LNPs and firefly luciferase mRNA; the generalizability to other lipid compositions, alternative mRNA payloads, or different buffer species remains to be established. Moreover, the mechanisms by which high citrate molarity impairs transfection—possibly through altered lipid packing or nanoparticle surface properties—require further elucidation. Nevertheless, the observed functional decline at higher buffer concentrations is likely relevant to a broad range of mRNA delivery and translation efficiency assay workflows.

Research Support Resources

For researchers aiming to benchmark or extend these findings, standardized reporter systems are crucial. EZ Cap™ Firefly Luciferase mRNA (SKU R1018) provides an in vitro transcribed, Cap 1–capped transcript with a stabilized poly(A) tail, suitable for use in mRNA-LNP formulation, gene regulation reporter assays, and in vivo bioluminescence imaging. Using such well-characterized Firefly Luciferase mRNA with Cap 1 structure enables reproducible assessment of how formulation parameters—including buffer molarity—affect delivery and expression outcomes (source: product_spec). For further perspectives on mRNA engineering and functional applications, see this internal article.